양세훈 교수 연구실
article|
인용수 13
·2022
Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation–Positive Non–Small Cell Lung Cancer
Jang Ho Lee, Eun Young Kim, Cheol‐Kyu Park, Shin Yup Lee, Min Ki Lee, S.H. Yoon, Jeong Eun Lee, Sang Hoon Lee, Seung Joon Kim, Sung Yong Lee, Jun Hyeok Lim, Tae Won Jang, Seung Hun Jang, Kye Young Lee, Seung Hyeun Lee, Sei Hoon Yang, Dong Won Park, Chan Kwon Park, Hye Seon Kang, Chang Dong Yeo, Chang‐Min Choi, Jae Cheol Lee
IF 4.6Cancer Research and Treatment
초록
Osimertinib demonstrated its clinical effectiveness and survival benefit for EGFR T790M mutation-positive in Korean patients with no new safety signals.
키워드
OsimertinibT790MMedicineDiscontinuationLung cancerInternal medicineOncologyEpidermal growth factor receptorCancerGastroenterology